176 related articles for article (PubMed ID: 26482266)
1. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.
Noguera-Julian M; Cozzi-Lepri A; Di Giallonardo F; Schuurman R; Däumer M; Aitken S; Ceccherini-Silberstein F; D'Arminio Monforte A; Geretti AM; Booth CL; Kaiser R; Michalik C; Jansen K; Masquelier B; Bellecave P; Kouyos RD; Castro E; Furrer H; Schultze A; Günthard HF; Brun-Vezinet F; Metzner KJ; Paredes R;
Clin Microbiol Infect; 2016 Feb; 22(2):191-200. PubMed ID: 26482266
[TBL] [Abstract][Full Text] [Related]
2. Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.
Neogi U; Shet A; Sahoo PN; Bontell I; Ekstrand ML; Banerjea AC; Sonnerborg A
J Int AIDS Soc; 2013 Feb; 16(1):18472. PubMed ID: 23443042
[TBL] [Abstract][Full Text] [Related]
3. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.
Fourati S; Malet I; Binka M; Boukobza S; Wirden M; Sayon S; Simon A; Katlama C; Simon V; Calvez V; Marcelin AG
AIDS; 2010 Sep; 24(15):2313-21. PubMed ID: 20729708
[TBL] [Abstract][Full Text] [Related]
4. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
5. E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.
Fourati S; Malet I; Lambert S; Soulie C; Wirden M; Flandre P; Fofana DB; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
AIDS; 2012 Aug; 26(13):1619-24. PubMed ID: 22695298
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S; Charpentier C; Storto A; Fofana DB; Soulié C; Fourati S; Visseaux B; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
J Antimicrob Chemother; 2013 Jun; 68(6):1237-42. PubMed ID: 23361642
[TBL] [Abstract][Full Text] [Related]
7. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
8. Minority resistant HIV-1 variants and the response to first-line NNRTI therapy.
Nicot F; Sauné K; Raymond S; Jeanne N; Carcenac R; Lefebvre C; Cuzin L; Marchou B; Delobel P; Izopet J
J Clin Virol; 2015 Jan; 62():20-4. PubMed ID: 25542465
[TBL] [Abstract][Full Text] [Related]
9. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
10. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors.
Gandhi SK; Siliciano JD; Bailey JR; Siliciano RF; Blankson JN
J Virol; 2008 Mar; 82(6):3125-30. PubMed ID: 18077705
[TBL] [Abstract][Full Text] [Related]
11. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz.
Covino DA; Purificato C; Catapano L; Galluzzo CM; Gauzzi MC; Vella S; Lefebvre E; Seyedkazemi S; Andreotti M; Fantuzzi L
Front Immunol; 2018; 9():1839. PubMed ID: 30135687
[TBL] [Abstract][Full Text] [Related]
13. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
14. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
15. [APOBEC3 hypermutations in HIV-1 infected cases in Turkey].
Sayan M; Simşek F; Ceran N; Dokuzoğuz B; Eraksoy H
Mikrobiyol Bul; 2013 Jul; 47(3):482-92. PubMed ID: 23971925
[TBL] [Abstract][Full Text] [Related]
16. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
[TBL] [Abstract][Full Text] [Related]
17. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
[TBL] [Abstract][Full Text] [Related]
18. Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.
Van Eygen V; Thys K; Van Hove C; Rimsky LT; De Meyer S; Aerssens J; Picchio G; Vingerhoets J
J Med Virol; 2016 May; 88(5):798-806. PubMed ID: 26412111
[TBL] [Abstract][Full Text] [Related]
19. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load.
Reddy K; Winkler CA; Werner L; Mlisana K; Abdool Karim SS; Ndung'u T;
AIDS; 2010 Jan; 24(2):195-204. PubMed ID: 19996938
[TBL] [Abstract][Full Text] [Related]
20. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.
Kim EY; Lorenzo-Redondo R; Little SJ; Chung YS; Phalora PK; Maljkovic Berry I; Archer J; Penugonda S; Fischer W; Richman DD; Bhattacharya T; Malim MH; Wolinsky SM
PLoS Pathog; 2014 Jul; 10(7):e1004281. PubMed ID: 25080100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
